北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月14日，京东健康发布公告称，2025年上半年实现营业 收入352.9亿元，同比增长24.5%；归属于公司所有者的期间盈利25.96亿元，同比增加27.45%。 ...

Core Insights - JD Health reported a total revenue of 35.3 billion yuan for the first half of 2025, representing a year-on-year growth of 24.5% [1] - The Non-IFRS net profit reached 3.57 billion yuan, showing a year-on-year increase of 35% [1] - The number of annual active users on JD Health's platform exceeded 200 million as of June 30, 2025 [1] Revenue and User Growth - JD Health's revenue growth is attributed to the enhancement of its self-operated, online platform, and instant retail channels [1] - The platform has over 150,000 merchants as of June 30, 2025 [1] Service Expansion and Innovations - JD Health's instant retail business has linked over 200,000 pharmacies nationwide, expanding online medical insurance payment services to nearly 200 million people [1] - The company is exploring innovative service models for retail pharmacies, including a collaboration with Beijing Children's Hospital to establish a pediatric pharmacy model [1] Healthcare Service Integration - JD Health has developed a comprehensive service loop covering "medical, testing, diagnosis, and medication" through its internet hospital [2] - The average daily consultation volume for JD Internet Hospital exceeded 500,000 as of June 30, 2025 [2] Home Healthcare Services - The home nursing service has expanded to cover 64 service items across 7 categories, including home care and traditional Chinese medicine care [2] - JD Health has also expanded its rapid testing service network, offering over 160 rapid testing services to users in 23 cities [2] AI Integration in Healthcare - JD Health launched the AI Jingyi series products for online scenarios, including AI doctors, pharmacists, nutritionists, and psychological consultants [2] - The AI Jingyi intelligent agents have served over 50 million users, enhancing the online health management experience [2]

Core Insights - JD Health reported a total revenue of 35.3 billion yuan for the first half of 2025, representing a year-on-year growth of 24.5%, with a Non-IFRS net profit of 3.57 billion yuan, up 35% [1] - The company has surpassed 200 million annual active users and has over 150,000 third-party merchants on its platform as of June 30, 2025 [1] - JD Health is focusing on enhancing its supply chain capabilities and integrating online and offline services to meet diverse health needs [1][5] Group 1: Financial Performance - Total revenue for the first half of 2025 reached 35.3 billion yuan, a 24.5% increase year-on-year [1] - Non-IFRS net profit was 3.57 billion yuan, reflecting a 35% growth compared to the previous year [1] Group 2: User Engagement and Market Position - The number of annual active users exceeded 200 million, indicating strong user engagement [1] - The platform has over 150,000 third-party merchants, enhancing its market presence [1][3] Group 3: Supply Chain and Product Offerings - JD Health is strengthening its supply chain through collaborations with leading pharmaceutical companies and health product suppliers [3] - The company launched over 30 innovative drugs online, reinforcing its position as the first stop for new specialty drugs [3] Group 4: Service Integration and User Experience - JD Health is enhancing its "medical, testing, diagnosis, and medication" service loop to cater to personalized health needs [5] - The average daily consultation volume at JD Internet Hospital exceeded 500,000, showcasing its service capacity [5] Group 5: AI Integration in Healthcare - The company is advancing AI applications in healthcare, with over 50 million users served by its AI products [6] - JD Health has launched the "JD Zuo Yi" AI product for hospitals, improving patient service processes [6] Group 6: Social Responsibility Initiatives - JD Health has engaged in various public welfare projects, providing support to over 31,000 rare disease patients [8] - The company donated over 170,000 medical care products to support earthquake relief efforts in Tibet [8] Group 7: Future Outlook - JD Health aims to enhance its supply chain and expand its healthcare service offerings while promoting AI applications for smarter healthcare solutions [8]

央广网北京8月14日消息（记者 马文静）8月14日，京东健康发布2025年中期业绩公告。2025年上 半年，京东健康总收入为人民币353亿元，同比增长24.5%；非国际财务报告准则指标下（Non-IFRS） 净利润达35.7亿元，同比增长35%。截至2025年6月30日，京东健康过去12个月的年度活跃用户数量突 破2亿；第三方合作商家数量显著增长，超过15万家，同比接近翻倍。 ...

新浪科技讯 8月14日晚间消息，京东健康发布2025年中期业绩公告。2025年上半年，京东健康总收入为 人民币353亿元，同比增长24.5%；非国际财务报告准则指标下（Non-IFRS）净利润达35.7亿元，同比增 长35%。 责任编辑：何俊熹 截至2025年6月30日，京东健康过去12个月的年度活跃用户数量突破2亿，第三方合作商家数量显著增 长，超过15万家，同比接近翻倍。 ...

智通财经APP获悉，8月14日，京东健康(06618)发布2025年中期业绩公告。2025年上半年，京东健康总 收入为人民币353亿元，同比增长24.5%；非国际财务报告准则指标下（Non-IFRS）净利润达35.7亿元， 同比增长35%。收入和净利润超出市场预期，显示出京东健康的长期价值持续释放。 2025年上半年，京东健康持续强化供应链能力，加快提升健康商品和服务供给质量、优化用户体验，从 而持续赢得更多消费者信赖。同时，京东健康还精准把握了行业增长趋势，积极推进人工智能技术驱动 服务模式创新，借助有利的行业政策支持，从而实现高质量业绩增长。 ...

8月14日，京东健康(06618)发布2025年中期业绩公告。2025年上半年，京东健康总收入为人民币353亿 元，同比增长24.5%；非国际财务报告准则指标下(Non-IFRS)净利润达35.7亿元，同比增长35%。收入和 净利润超出市场预期，显示出京东健康的长期价值持续释放。 2025年上半年，京东健康持续强化供应链能力，加快提升健康商品和服务供给质量、优化用户体验，从 而持续赢得更多消费者信赖。同时，京东健康还精准把握了行业增长趋势，积极推进人工智能技术驱动 服务模式创新，借助有利的行业政策支持，从而实现高质量业绩增长。 ...

Core Insights - JD Health reported a total revenue of RMB 35.3 billion for the first half of 2025, representing a year-on-year growth of 24.5% [1] - The Non-IFRS net profit reached RMB 3.57 billion, showing a year-on-year increase of 35% [1] - The annual active user count surpassed 200 million, marking a record high and indicating increased brand recognition and trust [1] User Growth and Marketing Strategies - The robust growth in annual active users is attributed to continuous improvements in user experience and a series of marketing strategies [1] - Collaborations with leading pharmaceutical companies and health product suppliers have expanded product offerings [1] - The company has further enhanced its service ecosystem, covering "medical, testing, diagnosis, and medication" to meet diverse and personalized health needs [1] - Key marketing campaigns such as "Happy Weight Loss" and "618 Free Order" have effectively increased user engagement on the platform [1]

Group 1: Market Overview - The Hong Kong stock market experienced a significant rally, with the Hang Seng Index rising by 2.58%, the Hang Seng China Enterprises Index increasing by 2.62%, and the Hang Seng Tech Index surging by 3.52% [2] - The total market turnover rose to HKD 2840.41 billion, with the short-selling amount on the main board at HKD 362.04 billion, resulting in a short-selling ratio of 14.162% [2] - Southbound capital flow turned negative, with a net outflow of HKD 8.277 billion, breaking a six-day streak of net inflows [2] Group 2: Sector Performance - The pharmaceutical sector saw a collective rise, driven by strong performances in pharmaceutical outsourcing, biopharmaceuticals, innovative drugs, AI healthcare, and internet healthcare [3] - The technology sector also showed broad strength, with sub-sectors like short videos, cloud computing, AI, and mobile gaming all experiencing gains, supported by positive earnings reports from several companies [4] - Consumer stocks were active across various categories, including entertainment, retail, and luxury goods, indicating a rebound in consumer sentiment [4] Group 3: Economic Indicators - The M2 money supply in China grew by 8.8% year-on-year in July, surpassing the previous value of 8.3% and market expectations of 8.4% [6] - The total social financing scale for the first seven months of the year reached CNY 23.99 trillion, which is CNY 5.12 trillion more than the same period last year, but below market expectations [7] - The consumer price index (CPI) in July returned to zero year-on-year, indicating ongoing deflationary pressures and a slow recovery in overall demand [9] Group 4: Real Estate and Consumer Trends - The real estate sector continues to face downward pressure, with a 13.2% year-on-year decline in sales for the top 100 real estate companies in the first seven months of 2025 [10] - Service consumption, particularly in tourism and hospitality, has shown signs of recovery, contributing to a temporary stabilization in core CPI [11] - The government is focusing on reducing excessive competition and improving the quality of industries, which may help alleviate deflationary pressures in the future [12]

Core Insights - Alibaba Health and Innovent Biologics have signed a strategic cooperation agreement to enhance post-disease management, supply chain, and digital marketing services for consumers [1][2] Group 1: Strategic Cooperation - The collaboration will focus on developing a post-disease management system that includes medication guidance, lifestyle consultation, and supportive services for patients [2] - Customized supply chain solutions will be provided by Alibaba Health to ensure compliance and safe delivery of temperature-sensitive medications [2] - Joint efforts will be made in digital marketing to promote scientific weight loss knowledge and facilitate online appointment services [2] Group 2: Company Profiles - Alibaba Health is a flagship platform of Alibaba Group that integrates online and offline resources in the pharmaceutical and health industry, offering a one-stop medical solution [1] - Innovent Biologics is a leading biopharmaceutical company in China with 16 innovative drugs on the market, including a recently approved weight loss drug [1][2] - The partnership aims to leverage the strengths of both companies in medical innovation and healthcare accessibility [2][3] Group 3: Future Aspirations - Alibaba Health aims to utilize its digital operations and supply chain advantages to efficiently deliver quality medications and services to patients [3] - There is an expectation to explore further collaborations in areas such as oncology and ophthalmology to provide sustainable high-quality healthcare services [3]